News List

Targeting specific DNA of Plasmodium may be effective in treating human malaria infection
2022-07-29

Targeting a parasite's DNA could be a more effective way to combat malaria, new research from th

Vijoice is the first FDA-approved PRS treatment
2022-07-07

2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera

Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib
2022-06-14

Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)
2022-05-13

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadel

Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib
2022-05-13

Recently, Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension t

AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
2022-03-11

AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
2022-02-11

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (

Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
2021-11-02

Novartis’ asciminib hasoutperformedPfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) stud

Hengrui announces new drug SHR7280
2021-10-16

On October 11, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that SHR0302, for the treat